Shots:

• The real-world clinical study compares glycemic outcomes for 1-736 individuals before & after using the InPen smart insulin pen for 90days with a CGM & showed a 2.3% increase in time in range for people with glucose GMI ( >8%) and 5% increase time in range for patients with GMI (>9.5%).
• Additionally- no patients have incidents of low blood sugar during the study period. The InPen also showed improvements in overall insulin dosing
• Along with the InPen study- the company also presents results from extended-use insulin infusion tubing which showed no significant increase in the total daily dose of insulin. The infusion set can be worn for up to seven days- no severe adverse events identified

Ref: Medtronic | Image: Medtronic